ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi springs for Protein Sciences

by Rick Mullin
July 17, 2017 | APPEARED IN VOLUME 95, ISSUE 29

Sanofi has agreed to buy Protein Sciences, a vaccines manufacturer, for $650 million. Based in Connecticut, Protein Sciences received FDA approval in October for Flublok Quadrivalent, which it touts as the only recombinant protein-based influenza vaccine to be cleared by the agency. “The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg-based vaccine,” says David Loew, head of Sanofi’s vaccines division. Sanofi will pay as much as $100 million more if certain milestones are hit.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment